Selecta Biosciences - SELB Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SELB shares.
View SELB analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year target prices for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 325.5% from the stock's current price.
View analysts price targets for SELB or view top-rated stocks among Wall Street analysts.

Selecta Biosciences' stock was trading at $1.13 at the beginning of 2023. Since then, SELB shares have increased by 24.8% and is now trading at $1.41.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SELB earnings forecast.

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings results on Thursday, March, 2nd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $16.80 million for the quarter, compared to analyst estimates of $12.72 million. Selecta Biosciences had a trailing twelve-month return on equity of 15.67% and a net margin of 31.94%.

ETFs with the largest weight of Selecta Biosciences (NASDAQ:SELB) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).First Trust Dow Jones Select Microcap Index Fund (FDM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Endurant Capital Management LP (2.47%), JPMorgan Chase & Co. (1.32%), Millennium Management LLC (1.08%), Marshall Wace LLP (0.86%), Renaissance Technologies LLC (0.80%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends.

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SELB stock can currently be purchased for approximately $1.41.

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $216.18 million and generates $110.78 million in revenue each year. The company earns $35.38 million in net income (profit) each year or $0.13 on an earnings per share basis.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.